SENATE FDA REFORM BILL WILL COST FDA $555 MIL. OVER SIX YEARS, CBO ESTIMATES; $430 MIL. WOULD STEM FROM PRODUCT REVIEW "HAMMER" PROVISION
This article was originally published in The Gray Sheet
The Senate FDA reform bill's "hammer" provision setting strict deadlines for FDA to reduce premarket submission backlogs and meet statutory review deadlines would cost the agency $430 mil. in additional resource expenditures and staffing over six years, the Congressional Budget Office estimates in its scoring of the reform bill (S 1477) reported out of the Labor and Human Resources Committee June 20. Overall, CBO foresees the agency incurring six-year costs of $555 mil. due to the measure.
You may also be interested in...
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.
The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.